Presence of BRCA mutations and a pre-chemotherapy AMH level of < 2NG/ML strongly predict risk of amenorrhea in women with breast cancer
Yükleniyor...
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
The likelihood of post-chemotherapy (ChT) amenorrhea is still empirically determined. Breast cancer is the most prevalent malignancy among the women of reproductive age. Our aim was to determine the predictors of amenorrhea risk post-ChT in women with breast cancer (ca). As acute amenorrhea (<12mo post-ChT) can be temporary, we used amenorrhea status 12- and 18-months post-ChT as the primary endpoint.
Açıklama
Anahtar Kelimeler
Brca Mutations, Breast Cancer, Pre-Chemotherapy, AMH Level
Kaynak
Fertility and Sterility
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
118
Sayı
4
Künye
Oktay, K. H., Turan, V., Bedoschi, G., Goldfarb, S., & Bang, H. (2023). Presence of BRCA mutations and a pre-chemotherapy AMH level of < 2NG/ML strongly predict risk of amenorrhea in women with breast cancer. Fertility and Sterility, 118(4), pp. E231-E231.
